November 29, 2016 - By Darrin Black
In a a research note revealed to clients on 29 November, Aegis Capital analyst just initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with Buy rating. The PT is set to $28.00.
Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $46 is the highest target while $22 is the lowest. The $34 average target is 93.18% above today’s ($17.6) stock price. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The firm earned “Hold” rating on Tuesday, June 14 by Brean Capital. The rating was downgraded by Zacks on Saturday, August 22 to “Hold”. As per Monday, November 23, the company rating was initiated by Guggenheim. SunTrust initiated the shares of RVNC in a report on Wednesday, March 23 with “Buy” rating. Suntrust Robinson maintained Revance Therapeutics Inc (NASDAQ:RVNC) rating on Tuesday, June 14. Suntrust Robinson has “Buy” rating and $22 price target.
It is down 10.61% since April 26, 2016 and is downtrending. It has underperformed by 15.87% the S&P500.
Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on March, 1. They expect $-0.88 earnings per share, down 6.02% or $0.05 from last year’s $-0.83 per share. After $-0.64 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.
Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.50, from 1.39 in 2016Q1. The ratio turned negative, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in the company for 380 shares. Bnp Paribas Arbitrage has 980 shares for 0% of their US portfolio. Blackrock Inc has 0% invested in the company for 1,893 shares. Teacher Retirement Sys Of Texas last reported 0% of its portfolio in the stock. United Financial Bank Va holds 1.04% or 77,177 shares in its portfolio. Essex Inv Management Ltd Liability Com accumulated 81,701 shares or 0.18% of the stock. Royal National Bank & Trust Of Canada reported 19,228 shares or 0% of all its holdings. Alps, a Colorado-based fund reported 39,990 shares. Rothschild Asset Mgmt Inc, a New York-based fund reported 10,539 shares. Great West Life Assurance Can reported 2,553 shares or 0% of all its holdings. Iguana Health Management Limited Liability Company accumulated 100,000 shares or 0.55% of the stock. Pointstate Capital Limited Partnership has 0.07% invested in the company for 250,000 shares. The New York-based Lombard Odier Asset (Usa) has invested 0.04% in Revance Therapeutics Inc (NASDAQ:RVNC). Citigroup last reported 6,358 shares in the company. Great Point Prtn Ltd Liability Corporation accumulated 0.08% or 21,665 shares.
Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 3 insider sales for $411,454 net activity. Ruegg Curtis sold $18,250 worth of stock. Browne L Daniel had sold 12,000 shares worth $178,199 on Wednesday, October 26.
Revance Therapeutics, Inc. is a biotechnology company. The company has a market cap of $490.71 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel , or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTSÂ® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”
Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.
Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black